Clinical Trials

DermatologicGenitourinaryThoracic

150 enrolled

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

15 enrolled

Adenocarcinoma, Neoplasms

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

126 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT05270213 2025-12-19

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

164 enrolled

Neoplasm Metastasis, Neoplasms

NCT05856981 2025-12-17

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

130 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

DermatologicHead & NeckSarcoma

56 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT03319940 2025-11-19

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

269 enrolled

Thoracic

Bites and Stings, Neoplasms, Small Cell Lung Carcinoma

NCT03486301 2025-11-12

EIK1001

87 enrolled

Neoplasms

NCT04840394 2025-11-12

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

1 enrolled

Neoplasms

NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

GastrointestinalGenitourinaryThoracic

145 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

149 enrolled

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05082610 2025-10-16

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

48 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT06188208 2025-10-16

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

125 enrolled

Neoplasms

NCT02964013 2025-10-14

KEYVIBE-001

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05514444 2025-10-09

MK-4464-001

64 enrolled

Neoplasms

NCT03564691 2025-10-07

MK-4830-001

470 enrolled

Neoplasms

NCT05501821 2025-09-25

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

16 enrolled

Neoplasms

NCT06983743 2025-09-11

AURORAS-1

200 enrolled

Neoplasm Metastasis, Neoplasms

NCT05359445 2025-09-09

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

95 enrolled

Neoplasms, Recurrence

NCT05378425 2025-09-09

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

90 enrolled

Neoplasm Metastasis, Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

GastrointestinalGenitourinaryThoracic

185 enrolled 28 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

39 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03260322 2025-04-24

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

169 enrolled

Neoplasms

NCT03948763 2025-01-28

V941-001

Phase 1 Terminated

70 enrolled 18 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

829 enrolled 100 charts

Neoplasms

NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

48 enrolled

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT02972034 2024-11-21

MK-8353-013

Phase 1 Terminated

111 enrolled 30 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03568058 2024-11-13

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

30 enrolled

Neoplasms

NCT03565445 2024-11-01

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & Neck

190 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03799003 2024-11-01

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Phase 1 Terminated

119 enrolled

DermatologicGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04130542 2024-10-31

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

276 enrolled

Neoplasms

NCT04659629 2024-10-01

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

59 enrolled

Neoplasms

NCT03447314 2024-09-23

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

54 enrolled 40 charts

Neoplasms

NCT03873883 2024-09-19

IO-001

119 enrolled

Neoplasms

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

DermatologicGastrointestinalLymphoidSarcomaThoracic

58 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT03530397 2024-06-24

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

401 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06307093 2024-03-12

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

DermatologicHead & NeckThoracic

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Lung Neoplasms, Melanoma, Neoplasms

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

104 enrolled

Neoplasms

NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

165 enrolled

Neoplasms

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

27 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02313272 2023-10-23

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas